Profile data is unavailable for this security.
About the company
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
- Revenue in JPY (TTM)28.71bn
- Net income in JPY3.04bn
- Incorporated2006
- Employees603.00
- LocationPeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
- Phone+81 442701300
- Websitehttps://www.peptidream.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Towa Pharmaceutical Co Ltd | 236.78bn | 11.74bn | 144.24bn | 4.30k | 11.74 | 0.926 | 4.51 | 0.6092 | 238.42 | 238.42 | 4,810.52 | 3,023.62 | 0.6134 | 1.62 | 3.73 | 55,090,510.00 | 3.04 | 4.73 | 3.80 | 6.39 | 34.66 | 41.27 | 4.96 | 8.06 | 1.48 | -- | 0.5686 | 19.97 | 26.11 | 17.46 | -86.17 | -19.46 | 14.66 | 13.63 |
| Sumitomo Pharma Co Ltd | 330.31bn | -173.72bn | 159.16bn | 6.25k | -- | 0.4626 | -- | 0.4819 | -437.26 | -437.26 | 831.40 | 864.73 | 0.2717 | 1.36 | 2.71 | 52,849,120.00 | -14.95 | 1.15 | -22.20 | 1.67 | 59.93 | 72.18 | -55.04 | 2.54 | 0.3785 | -- | 0.5452 | 41.44 | -0.8019 | 3.54 | -232.08 | -- | 0.6204 | 3.13 |
| KAKEN PHARMACEUTICAL CO., LTD. | 72.10bn | 2.97bn | 159.73bn | 1.13k | 44.50 | 0.9396 | 27.94 | 2.22 | 78.14 | 78.14 | 1,915.49 | 3,700.49 | 0.429 | 1.86 | 2.89 | 63,801,770.00 | 1.76 | 8.17 | 2.00 | 9.56 | 53.89 | 55.55 | 4.11 | 16.09 | 4.68 | -- | 0.0267 | 44.04 | -4.01 | -5.81 | -43.03 | -22.17 | 3.16 | 0.00 |
| Kissei Pharmaceutical Co Ltd | 73.72bn | 12.20bn | 177.27bn | 1.80k | 13.49 | 0.813 | 10.72 | 2.40 | 266.51 | 266.51 | 1,612.29 | 4,421.72 | 0.3213 | 1.68 | 2.60 | 41,067,970.00 | 5.38 | 3.21 | 5.87 | 3.47 | 48.23 | 52.39 | 16.74 | 11.10 | 4.51 | -- | 0.007 | 36.56 | 3.23 | -1.83 | -18.52 | 3.08 | 3.74 | 10.76 |
| Sawai Group Holdings Co Ltd | 185.31bn | 17.71bn | 255.20bn | 3.39k | 14.45 | 1.21 | 8.03 | 1.38 | 403.17 | 348.86 | 4,219.61 | 4,800.54 | 0.4905 | 1.32 | 2.75 | 54,615,090.00 | 3.62 | 1.14 | 5.08 | 1.56 | 30.41 | 36.92 | 7.39 | 2.24 | 1.31 | 71.96 | 0.291 | 81.02 | 3.37 | 3.58 | 144.81 | -2.01 | 10.06 | 0.00 |
| Peptidream Inc | 28.71bn | 3.04bn | 270.55bn | 603.00 | 88.81 | 6.68 | 49.47 | 9.42 | 23.43 | 23.43 | 221.37 | 311.32 | 0.4307 | 4.52 | 2.66 | 47,615,580.00 | 4.55 | -- | 5.34 | -- | 59.97 | -- | 10.57 | -- | 2.88 | 2.80 | 0.3551 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
| Tsumura & Co | 148.79bn | 16.76bn | 290.53bn | 4.03k | 17.17 | 1.06 | 9.93 | 1.95 | 220.44 | 220.44 | 1,954.80 | 3,569.48 | 0.3633 | 0.7326 | 2.27 | 36,903,020.00 | 4.55 | 4.98 | 5.57 | 6.03 | 47.57 | 53.82 | 12.53 | 12.74 | 2.90 | -- | 0.2115 | 30.98 | 8.10 | 3.51 | -12.50 | 2.59 | 6.41 | 0.00 |
| Nippon Shinyaku Co., Ltd. | 146.98bn | 24.14bn | 310.30bn | 2.19k | 12.32 | 1.38 | 10.63 | 2.11 | 358.40 | 358.40 | 2,182.30 | 3,192.25 | 0.6128 | 1.37 | 2.97 | 67,237,880.00 | 10.07 | 10.41 | 11.44 | 12.28 | 64.60 | 59.11 | 16.43 | 15.84 | 4.49 | -- | 0.0094 | 32.10 | 4.87 | 7.28 | -8.70 | 11.98 | 22.93 | 17.00 |
| Hisamitsu Pharmaceutical Co Inc | 141.71bn | 13.97bn | 325.24bn | 2.77k | 21.11 | 1.09 | 16.59 | 2.30 | 180.93 | 180.93 | 1,840.25 | 3,497.04 | 0.441 | 3.13 | 3.43 | -- | 4.49 | 4.22 | 5.25 | 4.82 | 55.73 | 58.62 | 10.18 | 10.03 | 3.76 | -- | 0.0078 | 52.55 | 10.42 | -0.2385 | 18.97 | -6.17 | 28.90 | 0.5989 |
Data as of May 02 2024. Currency figures normalised to PeptiDream Inc's reporting currency: Japanese Yen JPY
29.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| M&G Investment Management Ltd.as of 15 Dec 2023 | 9.80m | 7.54% |
| Taiyo Pacific Partners LPas of 30 Jun 2023 | 7.53m | 5.79% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 14 Jul 2023 | 4.44m | 3.42% |
| Nomura Asset Management Co., Ltd.as of 29 Mar 2024 | 3.23m | 2.49% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 3.19m | 2.45% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 3.06m | 2.35% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.09m | 1.61% |
| Nikko Asset Management Co., Ltd.as of 14 Jul 2023 | 1.80m | 1.39% |
| Comgest SAas of 30 Jun 2023 | 1.75m | 1.35% |
| Daiwa Asset Management Co. Ltd.as of 29 Mar 2024 | 1.55m | 1.19% |
More ▼
Data from 31 Dec 2023 - 25 Apr 2024Source: FactSet Research Systems Inc.
